Momordica Charantia Linnaeus, commonly known as bitter melon, has been traditionally used for its potential therapeutic properties, particularly in diabetes management. This paper aims to provide a comprehensive overview of the pharmaceutical properties, safety profile, and clinical efficacy of Momordica Charantia Linnaeus in diabetes management. The phytochemical composition of bitter melon, including charantin, polypeptide-p, and flavonoids, contributes to its antidiabetic, antioxidant, and anti-inflammatory effects (Ahmed et al., 2013; Grover & Yadav, 2004). Preclinical studies have demonstrated promising antidiabetic effects of bitter melon, such as blood glucose-lowering properties and preservation of pancreatic beta cell function (Ahmed et al., 2013; Grover & Yadav, 2004). However, clinical trials have yielded mixed results, highlighting the need for further research and standardization of study designs (Ooi et al., 2012). The safety profile of bitter melon is generally favorable, but some individuals may experience gastrointestinal disturbances and an increased risk of hypoglycemia (Grover & Yadav, 2004; Ooi et al., 2012). Additionally, bitter melon may interact with certain medications, necessitating caution and close monitoring in specific populations (Leung & Birtwhistle, 2009). In conclusion, Momordica Charantia Linnaeus shows potential as an adjunct therapy in diabetes management, but further research, including large-scale clinical trials, is needed to establish its efficacy, safety, and optimal usage guidelines (Grover & Yadav, 2004; Tiwari & Rao, 2002).